GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

MoonLake Immunotherapeutics MLTX · USD

Health Care · US listing · 🇺🇸 United States

Compare

12.62

+9.45%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Net income

−$227.3m

FY2020FY2025

Free cash flow

−$196.0m

FY2020FY2025

Shareholders' equity

$304.5m

FY2020FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020
Gross profit−$2.6m−$1.4m−$13,158−$12,358−$4,971—
Research and development$202.9m$112.8m$31.8m$42.0m$35.5m—
Operating income−$244.8m−$143.1m−$54.1m−$65.1m−$4.6m−$105,755
Net income−$227.3m−$118.9m−$36.0m−$64.5m−$4.5m−$90,838
Diluted earnings per share-3.53-1.89-0.60-1.66-0.12-0.01

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Total assets$424.4m$477.9m$526.5m$76.8m$9.7m$116.6m
Cash and short-term investments$394.0m$448.0m$511.0m$72.1m$8.0m$1.3m
Total liabilities$120.0m$24.5m$13.0m$8.1m$21.3m$4.2m
Debt$75.3m———$15.0m$58,063
Shareholders' equity$304.5m$446.8m$495.7m$48.9m−$11.6m$112.5m
Shares outstanding64m63m60m39m37m15m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations−$196.0m−$116.6m−$42.8m−$55.9m−$35.2m−$316,692
Capital spending−$35,000−$519,520−$284,634−$16,010−$50,706—
Free cash flow−$196.0m−$117.1m−$43.1m−$55.9m−$35.2m−$316,692
Dividends paid————−$51,915—

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue——————$101,850—
Gross profit—−$845,000−$751,000−$745,000−$742,000−$378,000$50,925−$32,515
Operating income−$61.7m−$70.0m−$65.2m−$71.4m−$60.7m−$47.5m−$49.6m−$43.1m
Net income−$61.8m−$69.7m−$62.4m−$69.7m−$55.2m−$39.9m−$45.6m−$35.4m
Diluted earnings per share-0.84-0.94-0.97-1.08-0.86-0.62-0.72-0.56
Cash from operations−$55.0m−$66.0m−$58.0m−$44.0m−$54.0m−$38.0m−$48.0m−$25.0m
Total assets$573.9m$400.4m$424.4m$414.3m$460.1m$511.3m$477.9m$518.2m
Cash and short-term investments$537.0m$357.9m$394.0m$380.5m$425.1m$480.1m$448.0m$493.9m
Debt$1.2m$99.9m$75.3m$75.2m$74.9m$74.5m$1.4m$1.8m
Shareholders' equity$428.2m$254.0m$304.5m$288.9m$353.7m$407.5m$446.8m$488.2m

Financial ratios

Data as of 5 Nov 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Return on equity-74.7%-26.6%-7.3%-131.9%39.0%-0.1%
Return on assets-53.6%-24.9%-6.8%-83.9%-46.9%-0.1%
Free cash flow yield-26.3%-15.9%-6.1%-12.4%-8.2%—
Earnings growth91.1%230.3%-44.2%1320.0%4900.8%—
Current ratio9.27x21.11x51.59x9.98x0.46x12.93x
Debt to equity0.25x0.00x0.00x0.00x-1.29x0.00x
Equity ratio71.7%93.5%94.1%63.6%-120.3%96.4%
Interest coverage-30.69x——-109.95x——
Buybacks as a share of market value-2.2%-5.3%-54.2%-5.2%-149.4%—

Growth per year

Compound annual rate

3 years5 years10 years
Operating income55.5%370.9%—
Net income52.2%378.3%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Price to earnings-3.7-28.7-100.5-6.3-49.0-1130.4

Market value over time

30 Oct 2020 to 4 Nov 2026, in USD

$30.8m$854.5m

Share price return

Finished calendar years

202520242023202220212020
Return-75%-13%539%55%-9%4%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 1-to-1 reverse split · 6 Apr 2022

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.